Redhill Biopharma Ltd (RDHL) - Total Assets
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) holds total assets worth $25.34 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Redhill Biopharma Ltd - Total Assets Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's total assets have evolved over time, based on quarterly financial data. Also see RDHL company net worth for the company's overall valuation and market capitalisation.
Redhill Biopharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Redhill Biopharma Ltd's total assets of $25.34 Million consist of 25.8% current assets and 74.2% non-current assets. Review Redhill Biopharma Ltd (RDHL) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $2.48 Million | 9.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.29 Million | 20.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Redhill Biopharma Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Redhill Biopharma Ltd's current assets represent 25.8% of total assets in 2025, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, down from 86.1% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 11.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 20.9% of total assets.
Redhill Biopharma Ltd Competitors by Total Assets
Key competitors of Redhill Biopharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Redhill Biopharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.56 | 1.69 |
| Quick Ratio | 0.34 | 0.42 | 1.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.69 Million | $-9.73 Million | $46.03 Million |
Redhill Biopharma Ltd - Advanced Valuation Insights
This section examines the relationship between Redhill Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 40.5% |
| Total Assets | $25.34 Million |
| Market Capitalization | $3.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Redhill Biopharma Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Redhill Biopharma Ltd's assets grew by 40.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual total assets of Redhill Biopharma Ltd from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.34 Million | +40.47% |
| 2024-12-31 | $18.04 Million | -21.71% |
| 2023-12-31 | $23.05 Million | -85.49% |
| 2022-12-31 | $158.87 Million | -12.32% |
| 2021-12-31 | $181.19 Million | +0.53% |
| 2020-12-31 | $180.24 Million | +143.24% |
| 2019-12-31 | $74.10 Million | +18.73% |
| 2018-12-31 | $62.41 Million | +8.84% |
| 2017-12-31 | $57.34 Million | -22.73% |
| 2016-12-31 | $74.21 Million | +11.05% |
| 2015-12-31 | $66.83 Million | +131.59% |
| 2014-12-31 | $28.86 Million | +101.23% |
| 2013-12-31 | $14.34 Million | -28.64% |
| 2012-12-31 | $20.10 Million | -0.45% |
| 2011-12-31 | $20.19 Million | +92.06% |
| 2010-12-31 | $10.51 Million | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more